Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pallone on supplements

This article was originally published in The Tan Sheet

Executive Summary

Recent statements by FDA Commissioner Mark McClellan, MD/PhD, implying a need to "crack down" on dietary supplements "create unnecessary concern among consumers and are grossly unfair to the industry as a whole," Rep. Frank Pallone (D-N.J.) states in Dec. 20 letter to agency head. Referring to McClellan's Dec. 18 announcement of FDA, FTC intentions to target misleading supplement claims, the Congressman notes such statements "give the impression that the entire industry is at fault, rather than those few manufacturers that are not in compliance" (1"The Tan Sheet" Dec. 23, 2002, p. 11). Pallone criticizes FDA's "ineffective and inefficient" attempts to implement DSHEA, requests meeting "to discuss federal legislation regarding" supplements and Congress' expectations for agency...

You may also be interested in...



Supplements For Smokers, Alcohol Users Targeted For FDA Enforcement

Dietary supplements marketed to smokers and drinkers are two of nine categories of products that "warrant close scrutiny" for enforcement, FDA says

Will AZ Legal Notice, Clotting Incidents Cloud Serum’s Fortunes?

AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of COVID-19 vaccines. Will this and the entry of a new challenger, Sputnik V, in the Indian market affect Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand for the partnered vaccine?

QUOTED. 13 April 2021. US FDA.

As medical organizations such as the Veterans Health Administration and Mayo Clinic are positioning themselves to become medical device manufacturers using 3D printing technologies, it opens challenges and opportunities. See what Mayo Clinic’s Sean McEligot said about it here.

Topics

UsernamePublicRestriction

Register

PS094973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel